1. Home
  2. HURC vs ENGN Comparison

HURC vs ENGN Comparison

Compare HURC & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hurco Companies Inc.

HURC

Hurco Companies Inc.

HOLD

Current Price

$22.52

Market Cap

143.0M

Sector

Industrials

ML Signal

HOLD

Logo enGene Holdings Inc.

ENGN

enGene Holdings Inc.

HOLD

Current Price

$1.70

Market Cap

117.2M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
HURC
ENGN
Founded
1968
1999
Country
United States
Canada
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
143.0M
117.2M
IPO Year
1995
2023

Fundamental Metrics

Financial Performance
Metric
HURC
ENGN
Price
$22.52
$1.70
Analyst Decision
Buy
Analyst Count
0
6
Target Price
N/A
$21.08
AVG Volume (30 Days)
17.8K
666.1K
Earning Date
06-05-2026
06-11-2026
Dividend Yield
N/A
N/A
EPS Growth
8.59
56.85
EPS
N/A
N/A
Revenue
$178,554,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$14.50
$1.40
52 Week High
$23.75
$12.25

Technical Indicators

Market Signals
Indicator
HURC
ENGN
Relative Strength Index (RSI) 58.29 39.65
Support Level $16.29 $1.68
Resistance Level $23.61 $1.84
Average True Range (ATR) 0.66 0.08
MACD 0.08 0.00
Stochastic Oscillator 98.43 20.00

Price Performance

Historical Comparison
HURC
ENGN

About HURC Hurco Companies Inc.

Hurco Companies Inc is an international industrial technology company that designs, manufactures, and sells computerized (CNC) machine tools for the metal cutting industry through a international sales and distribution network. Its proprietary control systems and software are sold as integral components of its machine tools. The Company also provides machine tool components, automation solutions, software options, upgrades, accessories, replacement parts, and related support services. It operates in the Americas, Europe, and Asia Pacific, with the Americas contributing the majority of revenue. Its core products include vertical and horizontal machining centers (mills), turning centers (lathes), and toolroom machines.

About ENGN enGene Holdings Inc.

enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.

Share on Social Networks: